placebo + docetaxel

placebo + docetaxel is a combination treatment used as a control arm in clinical trials, specifically in a Phase 2 study sponsored by Ascenta Therapeutics for patients with relapsed or refractory non-small cell lung cancer (NSCLC). Docetaxel is a semi-synthetic taxane that acts as an antineoplastic agent by promoting the assembly of tubulin into stable microtubules and inhibiting their disassembly, which leads to a marked decrease in free tubulin and causes cell cycle arrest. In this specific trial context, it was compared against the combination of AT-101 (a pan-Bcl-2 inhibitor) and docetaxel to evaluate the efficacy of adding a pro-apoptotic agent to standard chemotherapy. The placebo component in this regimen was administered orally as tablets to match the administration of the experimental drug AT-101.

Brand names

Taxotere

Other names

Placebo plus Docetaxel